Phase I study of erlotinib (tarceva) and temsirolimus (CCI-779) for patients with recurrent malignant gliomas (NABTC 04-02)

被引：0
|
作者：
Wen, P. Y.
Chang, S. M.
Kuhn, J.
Lamborn, K.
Robins, H. I.
Cloughesy, T.
Gilbert, M. R.
Yung, W. K. A.
Mehta, M.
DeAngelis, L. M.
Abrey, L. E.
Kesari, S.
Drappatz, J.
Lassman, A. B.
Dancey, J.
Prados, M. D.
机构：
[1] N Amer Brain Tumor Consortium, Bethesda, MD USA
[2] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA
来源：
NEURO-ONCOLOGY | 2006年 / 8卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：454 / 454
页数：1
相关论文
共 50 条
  • [11] Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
    Chang, SM
    Kuhn, J
    Wen, P
    Greenberg, H
    Schiff, D
    Conrad, C
    Fink, K
    Robins, HI
    Cloughesy, T
    De Angelis, L
    Razier, J
    Hess, K
    Dancey, J
    Prados, MD
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (04) : 427 - 435
  • [12] A Phase 1 Clinical Study of Temsirolimus (CCI-779) in Japanese Patients with Advanced Solid Tumors
    Fujisaka, Yasuhito
    Yamada, Yasuhide
    Yamamoto, Noboru
    Horiike, Atsushi
    Tamura, Tomohide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (08) : 732 - 738
  • [13] A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally recurrent endometrial cancer - NCICCTG IND 160.
    Oza, AM
    Elit, L
    Biagi, J
    Gotlieb, W
    Tonkin, KS
    Tsao, M
    Hedley, D
    Hansen, C
    Dancey, J
    Eisenhauer, E
    Seymour, L
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9099S - 9099S
  • [14] Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02)
    Wen, P. Y.
    Cloughesy, T.
    Kuhn, J.
    Lamborn, K.
    Abrey, L. E.
    Lieberman, F.
    Robins, H. I.
    Wright, J.
    Prados, M. D.
    Gilbert, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [15] Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
    Galanis, E
    Buckner, JC
    Maurer, MJ
    Kreisberg, JL
    Ballman, K
    Boni, J
    Peralba, JM
    Jenkins, RB
    Dakhil, SR
    Morton, RF
    Jaeckle, KA
    Scheithauer, BW
    Dancey, J
    Hidalgo, M
    Walsh, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5294 - 5304
  • [16] Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCICIND 160.
    Oza, A. M.
    Elit, L.
    Biagi, J.
    Chapman, W.
    Tsao, M.
    Hedley, D.
    Hansen, C.
    Dancey, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 121S - 121S
  • [17] Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572
    Schiff, David
    Sarkaria, Jann
    Decker, Paul
    Buckner, Jan
    Galanis, Evanthia
    Dancey, Janet
    Giannini, Caterina
    Brown, Paul
    Wiesenfeld, Martin
    Jaeckle, Kurt
    NEURO-ONCOLOGY, 2007, 9 (04) : 518 - 518
  • [18] Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179
    Oza, A. M.
    Kollmannsberger, C.
    Hirte, H.
    Welch, S.
    Siu, L.
    Mazurka, J.
    Sederias, J.
    Doyle, L. A.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [19] Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02)
    Prados, M.
    Gilbert, M.
    Kuhn, J.
    Lamborn, K.
    Cloughesy, T.
    Lieberman, F.
    Puduvalli, V.
    Robins, H. I.
    Lassman, A.
    Wen, P. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [20] Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma.
    Ghobrial, Irene M.
    Munshi, Nikhil
    Schlossman, Robert
    Chuma, Stacey
    Leduc, Renee
    Nelson, Marybeth
    Sam, Amy
    O'Connor, Kelly
    Harris, Brianna
    Warren, Diane
    Dollard, Akari M.
    Laubach, Jacob
    Vij, Ravi
    Campagnaro, Erica
    Birner, Ann
    Dixon-Lipscomb, Virginia
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2008, 112 (11) : 1266 - 1266
12345